Arvinas, Inc. (ARVN) stock
ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.76−0.06 (-0.81%)
Close on Nov 18, 2026Market cap $442.34MP/E 42.3Yield –
Arvinas operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Arvinas's operating income for the twelve months ending Jun 30, 2026 was -$18.10M. For fiscal 2025 it was -$118.50M. The highest annual figure on record is -$24.76M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$118.50M | – |
| FY2024 | Dec 31, 2024 | -$250.20M | – |
| FY2023 | Dec 31, 2023 | -$401.50M | – |
| FY2022 | Dec 31, 2022 | -$263.20M | – |
| FY2021 | Dec 31, 2021 | -$188.40M | – |
| FY2020 | Dec 31, 2020 | -$120.80M | – |
| FY2019 | Dec 31, 2019 | -$51.50M | – |
| FY2018 | Dec 31, 2018 | -$43.80M | – |
| FY2017 | Dec 31, 2017 | -$24.76M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $164.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$63.80M | -189.4% |
| Q4 FY2025 | Dec 31, 2025 | -$74.60M | – |
| Q3 FY2025 | Sep 30, 2025 | -$43.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$71.50M | – |
| Q1 FY2025 | Mar 31, 2025 | $71.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$58.20M | – |
| Q3 FY2024 | Sep 30, 2024 | -$60.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$48.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$83.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$165.30M | – |
| Q3 FY2023 | Sep 30, 2023 | -$73.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$74.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$87.70M | – |
| Q4 FY2022 | Dec 31, 2022 | -$75.60M | – |
| Q3 FY2022 | Sep 30, 2022 | -$64.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$65.80M | – |
| Q1 FY2022 | Mar 31, 2022 | -$57.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$47.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$47.30M | – |
| Q2 FY2021 | Jun 30, 2021 | -$51.90M | – |
| Q1 FY2021 | Mar 31, 2021 | -$41.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$39.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$31.75M | -676.7% |
| Q2 FY2020 | Jun 30, 2020 | -$26.48M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.79M | – |
| Q3 FY2019 | Sep 30, 2019 | $5.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$18.42M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.81M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.94M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.06M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.52M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.28M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.31M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.72M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.32M | – |
See a number that looks wrong?